Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toujeo in T2DM inadequately controlled with basal insulin
NCT02967237Phase 4Completed
- Sponsor
- Sanofi
- Start
- Jan 2016
- Primary completion
- Jul 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of insulin glargine in type 2 diabetes mellitus (T2DM), sponsored by Sanofi. Primary endpoint: Mean change from baseline in HbA1c at 24 weeks. Started Jan 2016; status: completed.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02967237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02967237.